Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
Greg Andrew Durm(Indiana University Health), Nasser H. Hanna(Ontario Institute for Cancer Research), Apar Kishor Ganti(University of Nebraska Medical Center), Mary J. Fidler, Naomi Fujioka(University of Minnesota), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Shadia I. Jalal(Indiana University Health), Borys Hrinczenko(Michigan State University), Salma K. Jabbour(Rutgers, The State University of New Jersey), Sandra K. Althouse(Indiana University School of Medicine), Lawrence Feldman(University of Illinois Chicago), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Jason Chesney(University of Louisville Hospital), Hirva Mamdani(Wayne State University)
Cited by 29
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k